Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how effective trastuzumab deruxtecan T-DXd is for patients in the US with HER2-positive IHC 3 solid tumors that are locally advanced, cannot be removed by surgery, or have spread to other parts of the body. These patients have already received prior systemic treatments for advanced disease and currently have no satisfactory treatment options. The study focuses on a real-world setting to better understand treatment outcomes outside of controlled clinical trials. This is a multicenter, hybrid observational study involving about 100 patients who start T-DXd treatment as part of their routine care following FDA guidelines. Patients with certain cancers like breast, colorectal, non-small cell lung, gastricgastroesophageal junction cancers, or blood cancers are not included. The study takes place at approximately 30 sites including community practices, hospitals, and academic centers to reflect typical care environments. Participants will be observed from the start of their T-DXd treatment with data collected on their response to therapy, how long the response lasts, time until treatment stops, and time until the next treatment begins. These outcomes will be tracked for up to 2.5 years after enrollment. No additional interventions are given beyond usual care, and patients will provide informed consent before joining the study.
Actively Recruiting
Researchers are collecting clinical data and biological samples from adults diagnosed with stage I, stage II, or operable stage III cancers in certain solid tumor types. This observational study aims to help develop tests that improve cancer detection and assess the risk of cancer returning. Participants continue to receive standard care from their own doctors throughout the study. Participants will provide blood and tumor tissue samples during their routine care. The study includes several tumor groups such as bladder cancer, esophageal cancer, gastric and gastroesophageal junction cancer, melanoma, non-small cell lung cancer, pancreatic cancer, and a mix of other solid tumors. Enrollment occurs either before or within three months after surgery, and no prior systemic therapy for the current cancer is allowed before joining. During the approximately five and a half years of involvement, participants will be observed with collection of blood and tissue samples as part of a biospecimen registry. Researchers will use this information to study molecular residual disease in solid tumors. All clinical data and samples will be gathered under routine care settings, with no additional treatment provided by the study team.